Lazard Asset Management
LENZ

Lazard Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Lazard Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12
Closed – – 2480
2024
Q2 		$0 Sell
12
-276
-96% -$4.82K ﹤0.01% 2456
2024
Q1 		$6K Sell
288
-122
-30% -$2.54K ﹤0.01% 1896
2023
Q4 		$7K Sell
410
-24
-6% -$396 ﹤0.01% 2110
2023
Q3 		$7K Buy
434
+21
+5% +$365 ﹤0.01% 2170
2023
Q2 		$7K Buy
413
+25
+6% +$500 ﹤0.01% 2200
2023
Q1 		$6K Buy
388
+73
+23% +$1.18K ﹤0.01% 2159
2022
Q4 		$7K Buy
+315
New +$7.3K ﹤0.01% 2240

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Lazard Asset Management's LENZ Position: Q3 2024 in Review

Lazard Asset Management sold out of LENZ Therapeutics (LENZ) in Q3 2024, closing a stake of 12 shares.

Lazard Asset Management first reported a position in LENZ in Q4 2022 and held it in 7 quarters. The position peaked at $7K in Q4 2023. 78 funds tracked by Wall St. Rank hold LENZ as of Q3 2024.

  • Lazard Asset Management reported no remaining LENZ Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 12 LENZ Therapeutics shares in Q3 2024.
  • Lazard Asset Management first reported a position in LENZ Therapeutics in Q4 2022 and held it in 7 quarters.
  • Lazard Asset Management's LENZ Therapeutics position peaked at $7K in Q4 2023.
  • 78 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.